EZR and neoplasm: Our data indicate that the chemosensitizing effect of anti-ezrin therapy largely affects disseminated cancer cells at their secondary organ site, as no significant changes in primary tumor regression or CTC levels were observed with the addition of NSC to DOX or DTX treatment.